A sulfonylurea drug that helps the pancreas release more insulin, lowering blood sugar levels.
A thiazolidinedione (tzd) drug that enhances the body's response to insulin, making cells more sensitive to it.
Type 2 diabetes mellitus when diet and exercise alone are not sufficient to control blood sugar levels.
This combination medication works by improving insulin sensitivity and increasing insulin secretion. Gliclazide stimulates insulin release from the pancreas, while Rosiglitazone makes the body's cells more responsive to insulin.
Store at room temperature, away from heat, light, and moisture. Keep out of reach of children.
Dosage should be determined by your doctor based on individual needs and response to treatment.
Typically taken once or twice daily with meals.
Do not crush, break, or chew the tablets. Swallow them whole with water.
Hypoglycemia (low blood sugar): Symptoms include sweating, dizziness, confusion, headache, and weakness.
Weight gain.
Fluid retention (edema).
Headache.
Nausea.
Diarrhea.
Heart failure.
Liver problems.
Bone fractures.
Increased risk of bladder cancer.
Alcohol can increase the risk of hypoglycemia.
May cause drowsiness and dizziness. Avoid driving or operating machinery until you know how this medication affects you.
Use only if the benefits outweigh the risks. Consult your doctor.
Not recommended for children.
May need dose adjustment in patients with kidney problems.
May need dose adjustment in patients with liver problems.
Package Insert
National Institutes of Health (NIH)
U.S. Food and Drug Administration (FDA)
American Diabetes Association (ADA)
